Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Probiotix HealthAQSE:PBX 21 Days Payable is 73.22 as of Jun. 2026, which is 28% below its 10-year median of 101.14. GuruFocus rates AQSE:PBX with a GF Score™ of 21/100 and a GF Value™ of £0.10 (Fairly Valued). The stock has 3 warning signs investors should review. Among 707 Biotechnology companies, Probiotix Health ranks worse than 53.32% on this metric.
The historical rank and industry rank for Probiotix Health's Days Payable or its related term are showing as below:
AQSE:PBX'
s Days Payable Range Over the Past 10 Years
Min: 38.4 Med: 101.14 Max: 142.4
Current: 93.82
During the past 2 years, Probiotix Health's highest Days Payable was 142.40. The lowest was 38.40. And the median was 101.14.
AQSE:PBX's Days Payable is ranked worse than 53.32% of 707
companies
in the Biotechnology industry
Industry Median: 111.24
vs AQSE:PBX: 93.82
Probiotix Health's Days Payable
declined
from Jun. 2025 (107.56) to Jun. 2026 (73.22).
It may suggest that Probiotix Healthaccelerated paying its suppliers.
The historical data trend for Probiotix Health's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Probiotix Health Days Payable Chart
Probiotix Health Annual Data
Trend
Dec24
Dec25
Days Payable
101.14
38.40
Probiotix Health Semi-Annual Data
Dec24
Jun25
Dec25
Jun26
Days Payable
72.85
107.56
114.20
73.22
AQSE:PBX vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, Probiotix Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Probiotix Health Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Probiotix Health's Days Payable distribution charts can be found below:
* The bar in red indicates where Probiotix Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Probiotix Health's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Probiotix Health (AQSE:PBX) has a Days Payable of 73.22 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Probiotix Health and its competitors. This is 28% below median its historical median of 101.14. Over the past decade, Probiotix Health's Days Payable has ranged from 38.40 to 142.40. According to the industry distribution chart, Probiotix Health ranks #377 out of 707 companies in the Biotechnology industry, placing it in the top 53.3%.
Is Probiotix Health's Days Payable too high?
Probiotix Health's current Days Payable of 73.22 is 28% below median its 10-year median of 101.14. Over the past 10 years, this metric has ranged from a low of 38.40 to a high of 142.40. The Biotechnology industry median Days Payable is 111.24. Probiotix Health's value of 73.22 is 34.2% below this industry median. Based on the distribution chart, Probiotix Health ranks #377 out of 707 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Probiotix Health has a GF Score™ of 21/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Probiotix Health's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Probiotix Health ranks #377 out of 707 companies for Days Payable. This places Probiotix Health in the lower half of its industry. The industry median Days Payable is 111.24. Probiotix Health's value of 73.22 is 34.2% below this benchmark. Historically, Probiotix Health's own Days Payable has ranged from 38.40 to 142.40 over the past decade. While the company's 10-year median is 101.14 vs. the industry median of 111.24, Probiotix Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.24, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Probiotix Health's current Days Payable of 73.22 is 34.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Probiotix Health and its competitors. For the Biotechnology industry, the median Days Payable is 111.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Probiotix Health's current Days Payable is 73.22, which is 28% below median its own 10-year median of 101.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Probiotix Health stock overvalued right now?
Based on GuruFocus' analysis, Probiotix Health (AQSE:PBX) is currently considered Fairly Valued. The stock's GF Value™ is £0.10, compared to a current price of £0.11 — trading 5% above its estimated fair value. The current Days Payable is 73.22, which is 28% below median its 10-year median of 101.14 and 34.2% below the Biotechnology industry median of 111.24. Probiotix Health's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Probiotix Health (AQSE:PBX), the current Days Payable is 73.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Probiotix Health (AQSE:PBX) Overvalued in 2026?
Based on GuruFocus' analysis, Probiotix Health stock appears to be overvalued.
The current stock price of £0.11 is trading 5% above its estimated GF Value™ of £0.10.
GuruFocus considers Probiotix Health to be Fairly Valued.
Key valuation signals for AQSE:PBX:
Days Payable: 73.22 (28% below median its 10-year median of 101.14)
GF Value™: £0.10 vs. price of £0.11 (5% above fair value)
Industry Position: 34.2% below the Biotechnology median (#377 of 707)
No single metric tells the full story. See the AQSE:PBX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Probiotix Health PLC is a life sciences company that develops probiotics to tackle cardiovascular disease and other lifestyle conditions that are affecting growing numbers of people across the world. The company has one class of business, in three geographical areas, being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry. Its geographical segments include the United Kingdom, the United States, and the Rest of the World. It generates the majority of its revenue from the United States.
21GF Score
Get the complete analysis for AQSE:PBX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AQSE:PBX has been successfully added to your 
